Skip to main content

Peer Review reports

From: Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III–IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial

Original Submission
9 Jan 2019 Submitted Original manuscript
17 Apr 2019 Reviewed Reviewer Report - Gregor Bond
18 Apr 2019 Reviewed Reviewer Report - Mateus Antunes
18 Apr 2019 Reviewed Reviewer Report - Cunyun Min
23 Apr 2019 Reviewed Reviewer Report - Catherine Carr
1 May 2019 Reviewed Reviewer Report - Cynthia Bell
8 May 2019 Reviewed Reviewer Report - Gowrie Balasubramaniam
8 Jun 2019 Author responded Author comments - Jing Gan
Resubmission - Version 2
8 Jun 2019 Submitted Manuscript version 2
10 Jun 2019 Reviewed Reviewer Report - Cunyun Min
13 Jun 2019 Reviewed Reviewer Report - Gregor Bond
13 Jun 2019 Reviewed Reviewer Report - Gowrie Balasubramaniam
24 Jun 2019 Reviewed Reviewer Report - Cynthia Bell
4 Jul 2019 Author responded Author comments - Jing Gan
Resubmission - Version 3
4 Jul 2019 Submitted Manuscript version 3
6 Jul 2019 Reviewed Reviewer Report - Gregor Bond
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
9 Jul 2019 Editorially accepted
7 Aug 2019 Article published 10.1186/s13063-019-3563-5

You can find further information about peer review here.

Back to article page